Is the use of t-PA as compared with streptokinase cost effective?
Armentano
R
R
Favaloro
R G
RG
D003362:Cost-Benefit Analysis; D006801:Humans; D008017:Life Expectancy; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000191:economics*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014481:United States; D026712:Value of Life
D013300:Streptokinase; D010959:Tissue Plasminogen Activator